SynapDx Corp. has reportedly secured $15.4 million in a funding round led by Google Ventures and joined by new investor Foundation Medical Partners and founding investors North Bridge Venture Partners and General Catalyst Partners. The funding will support the Massachusetts-based startup’s work on a blood-based autism spectrum disorder (ASD) diagnostic test that will allow clinicians to identify children with autism earlier than possible with existing diagnostics.

The company is apparently studying the genetic makeup of children clinically diagnosed with ASD to better understand how to design a more accurate blood test that will signal for the disorder. Google’s Andrew Conrad, newly appointed to SynapDx’s board, said, “The best diagnostic tests of our era will be developed at the nexus of advanced genomics and cutting edge informatics.” See SynapDx Corp. News Release and TechCrunch. com, July 22, 2013.